BRIEF-Halozyme Announces Global Collaboration And License Agreement With Gsk To Develop Subcutaneous Formulations Of Multiple Promising Oncology Targets

Halozyme Therapeutics, Inc.
GlaxoSmithKline plc Sponsored ADR

Halozyme Therapeutics, Inc.

HALO

0.00

GlaxoSmithKline plc Sponsored ADR

GSK

0.00

May 7 (Reuters) - Halozyme Therapeutics Inc HALO.O:

  • HALOZYME ANNOUNCES GLOBAL COLLABORATION AND LICENSE AGREEMENT WITH GSK TO DEVELOP SUBCUTANEOUS FORMULATIONS OF MULTIPLE PROMISING ONCOLOGY TARGETS

  • HALOZYME THERAPEUTICS INC - ANNOUNCES GLOBAL COLLABORATION AND LICENSE AGREEMENT WITH GSK

  • HALOZYME THERAPEUTICS INC - FIRST CLINICAL TRIAL PROJECTED TO INITIATE IN 2026

  • HALOZYME THERAPEUTICS INC - GSK TO MAKE UPFRONT AND MILESTONE PAYMENTS; HALOZYME ENTITLED TO ROYALTIES

  • HALOZYME THERAPEUTICS INC - COLLABORATION INCLUDES OPTION FOR ADDITIONAL FUTURE TARGETS

Source text: ID:nPn7RDj4ra

Further company coverage: HALO.O


This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.